The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Promising agents being explored in R/R MCL: bispecific antibodies and BTK inhibitors
Marcus Messmer, MD, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, discusses promising agents being explored for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), drawing focus on glofitamab and pirtobrutinib. Dr Messmer also comments on the excitement around the BOVen trial (NCT03824483), which is evaluating zanubrutinib, obinutuzumab, and venetoclax in patients with TP53-mutated MCL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
